Thyroid Hormones and Antithyroid Drugs

Classification

Replacement: levothyroxine(T4), liothyronine(T3, rarely alone). Antithyroid: thioamides(methimazole, carbimazole=prodrug, PTU) · iodide compounds(Lugol’s, high-dose KI) · radioactive iodine(I-131) · β-blockers(propranolol, symptomatic adjunct only).

Thyroid Hormone Replacement

Levothyroxine(T4): converted peripherally to more active T3 by deiodinases — mimics normal physiological tissue-level control + T4’s LONGER t½(~7 days) buffers missed doses/smoother levels than T3 would allow → WHY levothyroxine not liothyronine = 1st-line despite T3 being more active. Absorption ↓by Ca2+/iron/antacids/fibre(chelation, SAME mechanism as tetracyclines/fluoroquinolones) → take EMPTY STOMACH, separated in time.

Antithyroid — Mechanism

Thioamides: inhibit thyroid peroxidase(iodide oxidation+organification+coupling) → blocks NEW synthesis, existing stored hormone still released → clinical effect takes WEEKS(stores must deplete first — same logic as warfarin’s delayed onset). PTU has ADDITIONAL mechanism: also inhibits peripheral deiodinase(T4→T3 conversion) → extra/faster benefit in severe thyrotoxicosis → PTU preferred for THYROID STORM(not methimazole) — distinguishing point despite shared primary mechanism.

Iodide(high-dose): paradoxically INHIBITS synthesis/release despite being normal substrate — Wolff-Chaikoff effect(large iodide load → autoregulatory suppression of organification/release) = genuine protective mechanism, deliberately exploited. RAPID onset(hours-days) but TRANSIENT(thyroid “escapes” in 1-2wk, resumes normal handling) → used for SHORT-TERM preop prep(↓vascularity before thyroidectomy) + thyroid storm(rapid control while thioamides’ slower effect takes hold), NEVER sole long-term therapy(escape phenomenon).

Radioactive iodine(I-131): taken up via SAME sodium-iodide symporter as normal iodide → concentrates in thyroid(targeted delivery, spares surrounding tissue) → beta-emission → gradual cellular destruction over weeks. Definitive Rx: Graves’, toxic nodular goitre. ABSOLUTE CI in PREGNANCY(crosses placenta, concentrates in fetal thyroid once iodine-avid 2nd trimester → fetal hypothyroidism/cretinism).

Propranolol: does NOT affect synthesis/release at all — rapid symptomatic relief of ADRENERGIC symptoms(tachycardia, tremor, anxiety — thyroid excess UPREGULATES/sensitizes β-receptors, β-block addresses this DOWNSTREAM consequence, not hormone excess itself). Treats SYMPTOMS via separate mechanism — rapid adjunct ALONGSIDE(never instead of) genuine antithyroid therapy.

Adverse Effects

Levothyroxine: overdose = iatrogenic hyperthyroidism SE(tachycardia, weight loss, osteoporosis chronic excess, AF risk esp elderly) — dose-related exaggeration of OWN mechanism, not separate off-target toxicity(same logic as many hormone-replacement therapies).

Thioamides: AGRANULOCYTOSIS = most feared, idiosyncratic, abrupt onset → counsel: seek IMMEDIATE care for fever/sore throat during therapy(early neutropenia sign, don’t assume routine infection) — same counselling importance as clozapine. PTU: specific ADDITIONAL hepatotoxicity risk(rare, severe, incl fulminant failure) → methimazole generally preferred EXCEPT where PTU’s advantages matter(thyroid storm; traditionally 1st trimester pregnancy — methimazole’s teratogenic risk[aplasia cutis, malformations] vs PTU’s own hepatotoxicity = trade-off limited to early pregnancy specifically, not blanket preference).

Clinical Relevance

Different agents intervene at genuinely DIFFERENT points+timescales: thioamides=block new synthesis(slow, weeks, definitive) · iodide=transient autoregulatory suppression(fast, days, self-limiting) · RAI=direct tissue destruction(gradual weeks, permanent) · propranolol=symptoms only, no hormone effect(immediate, purely symptomatic). Recognizing WHICH mechanism-timescale pairing a scenario needs(thyroid storm = LAYER several together, not rely on one) = the actual clinical reasoning tested.

Classification

Thyroid hormone replacement: levothyroxine (T4), liothyronine (T3, rarely used alone given short half-life/narrow therapeutic window).

Antithyroid drugs:

Thioamides: methimazole (carbimazole is its prodrug), propylthiouracil (PTU)
Iodide compounds: Lugol’s iodine, potassium iodide (high-dose)
Radioactive iodine: I-131
β-blockers: propranolol (symptomatic adjunct, not a true antithyroid drug)

Thyroid Hormone Replacement

Levothyroxine (T4): synthetic T4, converted peripherally to the more biologically active T3 by deiodinase enzymes in target tissues — this peripheral conversion, rather than direct T3 administration, mimics the body’s normal physiological regulation (allowing tissue-level control over local T3 availability) and provides more stable, predictable plasma levels than T3 itself (T4’s longer half-life, roughly 7 days, buffers against missed doses and produces smoother levels than T3’s much shorter half-life would allow) — the specific pharmacokinetic reason levothyroxine, not liothyronine, is standard first-line replacement therapy despite T3 being the more active hormone. Absorption is reduced by numerous common co-administered substances — calcium/iron supplements, antacids, and dietary fibre all impair absorption via a chelation-type mechanism analogous to the cation interactions already seen with tetracyclines/fluoroquinolones — the specific, practical reason levothyroxine is taken on an empty stomach, well separated in time from these substances.

Antithyroid Drugs — Mechanism

Thioamides (methimazole, PTU): inhibit thyroid peroxidase, the enzyme responsible for iodide oxidation, organification (incorporation of iodine into tyrosine residues on thyroglobulin), and coupling of iodotyrosines into T3/T4 — blocking new hormone synthesis, though existing stored hormone in the colloid remains available for release, which is why the clinical effect takes several weeks to become apparent (the pre-existing hormone store must be depleted first, the same “existing stores must run down” pharmacokinetic logic already seen for warfarin’s delayed onset under Blood). PTU has an additional, second mechanism genuinely distinct from methimazole: it also inhibits peripheral deiodinase, the enzyme converting T4 to the more active T3 in peripheral tissues — this additional peripheral action gives PTU a modest additional/faster benefit in severely thyrotoxic states, the specific reason PTU (not methimazole) is preferred for thyroid storm, a genuinely distinguishing, examined point between two drugs that otherwise share the same primary mechanism.

Iodide compounds (high-dose): paradoxically inhibit thyroid hormone release and synthesis at high dose despite iodide being a normal substrate for hormone synthesis — the Wolff-Chaikoff effect, where a large iodide load transiently and autoregulatorily suppresses thyroid hormone organification/release, a genuine physiological protective mechanism against iodide-induced hyperthyroidism that antithyroid therapy deliberately exploits. This effect is rapid in onset (within hours to days) but transient (the thyroid typically “escapes” the Wolff-Chaikoff effect within 1–2 weeks and resumes normal hormone handling) — this rapid-onset-but-transient property is exactly why high-dose iodide is used specifically for short-term preoperative preparation (reducing thyroid vascularity/friability before thyroidectomy) and for acute thyroid storm management (rapid symptom control while thioamides’ slower-onset definitive effect takes hold), never as sole long-term therapy given the escape phenomenon.

Radioactive iodine (I-131): taken up by the thyroid via the same sodium-iodide symporter used for normal iodide uptake (a genuinely elegant targeted-delivery mechanism — the radioactive isotope is concentrated specifically in thyroid tissue by the gland’s own normal physiology, sparing surrounding tissue), where its beta-particle emission causes localized cellular damage/destruction over weeks, gradually reducing functional thyroid tissue — used for definitive treatment of Graves’ disease and toxic nodular goitre, and absolutely contraindicated in pregnancy (crosses the placenta, concentrates in the fetal thyroid once it becomes iodine-avid in the second trimester, causing fetal hypothyroidism/cretinism) — a specific, high-yield, mechanism-driven contraindication.

Propranolol: does not affect thyroid hormone synthesis or release at all, but provides rapid symptomatic relief of the adrenergic-mediated symptoms of hyperthyroidism (tachycardia, tremor, anxiety — thyroid hormone excess sensitizes/upregulates β-adrenergic receptors, so β-blockade addresses this downstream consequence rather than the thyroid hormone excess itself) — a specific, examined point that propranolol treats the symptoms of thyrotoxicosis via a completely separate mechanism, not the underlying hormone excess, and is used as a rapid-acting adjunct alongside (never instead of) a genuine antithyroid therapy.

Adverse Effects

Levothyroxine: adverse effects are essentially those of iatrogenic hyperthyroidism if overdosed (tachycardia, weight loss, osteoporosis with chronic excess, atrial fibrillation risk particularly in elderly patients) — worth understanding as dose-related exaggeration of the hormone’s own physiological effect rather than a separate, off-target toxicity, the same “adverse effect is just the drug’s own mechanism taken too far” logic that applies to many hormone-replacement therapies generally.

Thioamides: agranulocytosis is the most feared, specifically-examined adverse effect — idiosyncratic, can occur abruptly, and patients must be counselled to seek immediate medical attention for fever/sore throat during therapy (an early warning sign of neutropenia) rather than assuming a routine infection — the same class of counselling importance already seen for clozapine’s agranulocytosis risk under Antipsychotic and Antimanic Drugs. PTU carries a specific, additional hepatotoxicity risk (rare but severe, including fulminant hepatic failure) that has shifted routine preference toward methimazole except in the specific situations where PTU’s distinguishing advantages matter (thyroid storm, and traditionally the first trimester of pregnancy, where methimazole carries a specific teratogenic risk — aplasia cutis and other malformations — that PTU is thought to carry less of, though PTU’s own hepatotoxicity risk means the trade-off is specifically limited to early pregnancy rather than a blanket preference).

Clinical Relevance

The organizing theme across antithyroid therapy is that different agents intervene at genuinely different points and timescales: thioamides block new synthesis (slow onset, weeks, definitive), iodide exploits a transient autoregulatory suppression (fast onset, days, self-limiting), radioactive iodine destroys tissue directly (gradual, over weeks, permanent), and propranolol addresses symptoms without touching hormone levels at all (immediate, purely symptomatic) — recognizing which mechanism-timescale pairing a given clinical scenario needs (rapid symptom control in thyroid storm requires layering several of these together, not relying on any single mechanism) is the actual clinical reasoning this topic is testing.

Thyroid hormone synthesis pathway (iodide trapping → organification → coupling) with thioamide and Wolff-Chaikoff blocking points marked.
Onset-timescale comparison of the four antithyroid interventions (propranolol=immediate, iodide=days, thioamides=weeks, RAI=weeks-permanent).